XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2018
Jun. 15, 2021
Dec. 31, 2020
Collaboration And Other Agreements [Line Items]                  
Revenues   $ 15,662 $ 18,253   $ 63,300 $ 52,192      
Common stock, par value (in dollars per share)   $ 0.01     $ 0.01       $ 0.01
Deferred revenue, current   $ 16,314     $ 16,314       $ 4,456
Deferred revenue, net of current portion   9,575     9,575       6,926
2018 Zai Lab Agreement | Zai Labs                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment             $ 25,000    
Non-refundable upfront payment, net of tax withholding             22,500    
Nonrefundable payment tax withholding             $ 2,500    
Potential development and regulatory milestone payments under agreement       $ 140,000          
Development and regulatory milestones recognized       4,000          
Revenues, net of tax withholding       3,600   3,600      
Revenues, tax withholding       $ 400          
Deferred revenue   0     0       $ 0
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum                  
Collaboration And Other Agreements [Line Items]                  
Potential proceeds from royalties (percent)             20.00%    
Zai Lab Agreement, TRIDENT molecule | Zai Labs                  
Collaboration And Other Agreements [Line Items]                  
Potential proceeds from royalties (percent)             10.00%    
Zai Lab Clinical Supply Agreements | Zai Labs                  
Collaboration And Other Agreements [Line Items]                  
Revenues   600 $ 500   2,300 $ 1,900      
2021 Zai Lab Agreements | Zai Labs                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment $ 25,000                
Potential development and regulatory milestone payments under agreement               $ 800,000  
Deferred revenue   17,800     17,800        
Revenues   3,700     18,100        
Opt-in fee               $ 85,000  
Proceeds of stock sale 30,000                
Sales of stock purchase price (in dollars per share)               $ 31.3  
Potential commercial milestone payments under agreement               $ 600,000  
Collaborative agreement transaction price               $ 40,400  
Variable consideration recognized 5,000                
Deferred revenue, current   13,600     13,600        
Deferred revenue, net of current portion   $ 4,200     $ 4,200        
2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital                  
Collaboration And Other Agreements [Line Items]                  
Premium received on stock purchase $ 10,400